The TROP-2 targeted therapy market presents key opportunities driven by rising cancer prevalence, particularly in challenging tumor types. Growth is supported by advancements in precision medicine, ...

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of TROP-2-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about TROP-2 ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab ...

-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated preclinical monotherapy efficacy profile, the ...

Oncotarget recently published "Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer" which reported that the authors investigated whether ...

First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC). This ...

Background Endometrial cancer is the most common gynecologic malignancy in developed countries. Trop-2 is a glycoprotein involved in cellular signal transduction and is differentially overexpressed ...

Androgen deprivation therapy in the treatment of prostate cancer and dementia risk: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This ...

Researchers from Duality Biologics (Suzhou) Co. Ltd. presented preclinical data for a novel Trop-2-targeting antibody-drug conjugate (ADC), DB-1305, being developed for the treatment of solid tumors.

*Because of the small number of events (deaths and progressions) in the G1 EEC category, the confidence interval was not reliable.